MGUS et traitements biologiques : que faire ?
-
Published:2017-12
Issue:6
Volume:84
Page:472-474
-
ISSN:1169-8330
-
Container-title:Revue du Rhumatisme
-
language:fr
-
Short-container-title:Revue du Rhumatisme
Author:
Lemieux-Blanchard Émilie
Reference19 articles.
1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group;International Myeloma Working Group;Br J Haematol,2003
2. Monoclononal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus, perspectives, risk factors for progression, and guidelines for monitoring and management;Kyle;Leukemia,2010
3. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review;Wadhera;Mayo Clinic Proc,2010
4. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders;Brown;Blood,2008
5. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS);Bird;Br J Haematol,2009